| Kaihan Fakhar, | |
|
8600 Nicollet Ave S, Bloomington, MN 55420-2824 | |
| (952) 541-2800 | |
| (952) 886-7015 |
| Full Name | Kaihan Fakhar |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 9 Years |
| Location | 8600 Nicollet Ave S, Bloomington, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114312980 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 69906 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Regions Hospital | Saint paul, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Healthpartners Medical Group | 1759293954 | 1430 |
News Archive
The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.
BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral® System for prevention of Oral Mucositis, one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.
Glioblastoma is the most aggressive cancer that originates in the brain. Current therapies can slow the disease, but more often than not can't cure it.
› Verified 2 days ago
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031105000417 |
News Archive
The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.
BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral® System for prevention of Oral Mucositis, one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.
Glioblastoma is the most aggressive cancer that originates in the brain. Current therapies can slow the disease, but more often than not can't cure it.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kaihan Fakhar, 8170 33rd Ave S # Ms 21110q, Minneapolis, MN 55425-4516 Ph: () - | Kaihan Fakhar, 8600 Nicollet Ave S, Bloomington, MN 55420-2824 Ph: (952) 541-2800 |
News Archive
The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.
BrainCool AB, a Swedish medical device innovator, and a world leader in medical cooling technology for therapeutic hypothermia (brain cooling) and oncology, is pleased to announce that it has completed patient recruitment in the Scandinavian multi-center pivotal trial of 180 patients to investigate the patented Cooral® System for prevention of Oral Mucositis, one of the most debilitating side-effects of both standard and high-dose chemotherapeutic oncology treatments.
Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has submitted to the U.S. Food & Drug Administration a New Drug Application (NDA) seeking approval to market low-dose mesylate salt of paroxetine (LDMP) for the treatment of vasomotor symptoms associated with menopause.
Glioblastoma is the most aggressive cancer that originates in the brain. Current therapies can slow the disease, but more often than not can't cure it.
› Verified 2 days ago
Honora E. Kennedy, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-567-6156 | |
Mehdi Roozbahani, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 9801 Dupont Ave S Ste 110, Bloomington, MN 55431 Phone: 612-355-6510 Fax: 612-713-9360 | |
Elizabeth A Davis, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S, Suite 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-884-2656 | |
Jefferson Berryman, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S Ste 200, Bloomington, MN 55431 Phone: 952-888-5800 Fax: 952-567-6156 | |
Jill Suzanne Melicher Larson, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 9801 Dupont Ave S, 200, Bloomington, MN 55431 Phone: 952-888-5800 | |
Thomas Lang, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 7920 Old Cedar Ave S, Bloomington, MN 55425 Phone: 952-428-1800 |